The addition of the immunotherapy pembrolizumab (Keytruda) to standard presurgical chemotherapy improved pathological complete response (pCR) rates for patients with triple-negative breast cancer (TNBC). Moreover, the continuation of pembrolizumab following surgery also showed early signs of improvement in ...
The presence of two or more warning signs was associated with a concurrent laboratory-confirmed diagnosis of severe dengue at hospital admission. Thus, a cumulative score combining simple clinical parameters and first-line laboratory findings could be used to accurately predict dengue virus infection in...
In the U.S., KEYTRUDA has two approved indications in TNBC: for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery; and in combination with chemotherapy for ...
The more we educate women on these factors, signs, and symptoms, the more we empower them to take control of their health and increase the chances of early cancer detection. However, it is not always possible to detect breast cancer in its earliest stages. Some forms or subcla...
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved ...
Though the studies have proved that EGCG can control the growth of TNBC tumor, no clinical trials have been conducted to date. The main drawbacks of using this molecule are the poor bioavailability and stability, which can be overcome by designing micro and nanoparticle-based formulations of this...
6. Tuan NM, Nhan HT, Chau NVV, Hung NT, Tuan HM, Tram TV, Ha NL, Loi P, Quang HK, Kien DTH, Hubbards S, Chau TNBC, Wills B, Wolbers M, Simmons CP. Sensitivity and specificity of a novel classifier for the early diagnostic of dengue. PLoS Negl Trop Dis. 2015;9(4):e0003638...
2.2.1. Genotype Genotype analysis of CTCs in breast cancer is tuned to detect the most common driver mutations and to assess the difference between CTCs and primary tumor. Frequently mutated genes in breast cancer CTCs include TP53 (mostly in TNBC), PIK3CA, ERBB2, KRAS and ESR1. Moreover,...